The collagen receptor glycoprotein VI promotes platelet-mediated aggregation of β-amyloid

Multiple receptors on platelets drive Alzheimer’s disease–associated amyloid deposits in brain vessels. Unclogging amyloid from arteries Cerebral amyloid angiopathy (CAA) is a common feature of Alzheimer’s disease in which the deposition of amyloid in vessels in the brain impairs blood flow. Amyloid can activate platelets, which promotes amyloid aggregation. Using platelets from patients and mice, Donner et al. found that blocking the collagen receptor GPVI may reduce CAA. Amyloid bound to GPVI on platelets and stimulated the release of fibrinogen that both clustered with soluble amyloid and bound a platelet-surface integrin that further promoted amyloid aggregation. Blockade of GPVI or the integrin reduced amyloid aggregation in platelet cultures, and loss of GPVI reduced the adhesion of amyloid-activated platelets in arteries in mice, revealing a potential therapeutic target to ameliorate CAA in patients. Cerebral amyloid angiopathy (CAA) and β-amyloid (Aβ) deposition in the brain parenchyma are hallmarks of Alzheimer’s disease (AD). We previously reported that platelets contribute to Aβ aggregation in cerebral vessels by secreting the factor clusterin upon binding of Aβ40 to the fibrinogen receptor integrin αIIbβ3. Here, we investigated the contribution of the collagen receptor GPVI (glycoprotein VI) in platelet-induced amyloid aggregation. Using platelets isolated from GPVI–wild type and GPVI-deficient human donors and mice, we found that Aβ40 bound to GPVI, which induced the release of ATP and fibrinogen, resulting in platelet aggregation. Binding of Aβ40 to integrin αIIbβ3, fibrinogen, and GPVI collectively contributed to the formation of amyloid clusters at the platelet surface. Consequently, blockade of αIIbβ3 or genetic loss of GPVI reduced amyloid fibril formation in cultured platelets and decreased the adhesion of Aβ-activated platelets to injured carotid arteries in mice. Application of losartan to inhibit collagen binding to GPVI resulted in decreased Aβ40-stimulated platelet activation, factor secretion, and platelet aggregation. Furthermore, the application of GPVI- or integrin-blocking antibodies reduced the formation of platelet-associated amyloid aggregates. Our findings indicate that Aβ40 promotes platelet-mediated amyloid aggregation by binding to both GPVI and integrin αIIbβ3. Blocking these pathways may therapeutically reduce amyloid plaque formation in cerebral vessels and the brain parenchyma of patients.

[1]  C. Van Geet,et al.  Blood platelet research in autism spectrum disorders: In search of biomarkers , 2019, Research and practice in thrombosis and haemostasis.

[2]  Natalie S. Poulter,et al.  Comparison of the GPVI inhibitors losartan and honokiol , 2019, Platelets.

[3]  H. Gohlke,et al.  Relevance of N-terminal residues for amyloid-β binding to platelet integrin αIIbβ3, integrin outside-in signaling and amyloid-β fibril formation. , 2018, Cellular signalling.

[4]  S. Watson,et al.  Does fibrin(ogen) bind to monomeric or dimeric GPVI, or not at all? , 2018, Platelets.

[5]  R. Martins,et al.  Oligomeric and fibrillar amyloid beta 42 induce platelet aggregation partially through GPVI , 2018, Platelets.

[6]  S. Watson,et al.  Immobilized fibrinogen activates human platelets through glycoprotein VI , 2018, Haematologica.

[7]  G. Alexopoulos,et al.  Strategies for dementia prevention: latest evidence and implications , 2017, Therapeutic advances in chronic disease.

[8]  S. Tucker,et al.  Platelets and cancer angiogenesis nexus , 2017, Cancer and Metastasis Reviews.

[9]  X. Tong,et al.  Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease , 2017, The Journal of Neuroscience.

[10]  M. Prince,et al.  Recent global trends in the prevalence and incidence of dementia, and survival with dementia , 2016, Alzheimer's Research & Therapy.

[11]  Holger Gohlke,et al.  Platelets contribute to amyloid-β aggregation in cerebral vessels through integrin αIIbβ3–induced outside-in signaling and clusterin release , 2016, Science Signaling.

[12]  W. Bergmeier,et al.  Platelet immunoreceptor tyrosine‐based activation motif (ITAM) and hemITAM signaling and vascular integrity in inflammation and development , 2016, Journal of thrombosis and haemostasis : JTH.

[13]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[14]  H. Ni,et al.  Platelets in hemostasis and thrombosis: Novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis , 2015, Journal of biomedical research.

[15]  S. Watson,et al.  Fibrin activates GPVI in human and mouse platelets. , 2015, Blood.

[16]  R. Storey,et al.  The role of platelets in inflammation , 2015, Thrombosis and Haemostasis.

[17]  S. Watson,et al.  Activation of glycoprotein VI (GPVI) and C-type lectin-like receptor-2 (CLEC-2) underlies platelet activation by diesel exhaust particles and other charged/hydrophobic ligands. , 2015, The Biochemical journal.

[18]  G. Jondeau,et al.  Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan , 2015, PloS one.

[19]  P. Metharom,et al.  The functional role of platelets in the regulation of angiogenesis , 2015, Platelets.

[20]  L. Donner,et al.  Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer's disease. , 2014, Cellular signalling.

[21]  K. Freson,et al.  The contribution of platelet studies to the understanding of disease mechanisms in complex and monogenetic neurological disorders , 2014, Developmental medicine and child neurology.

[22]  S. Strickland,et al.  A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer’s disease mice , 2014, The Journal of experimental medicine.

[23]  N. S. Gowert,et al.  Blood Platelets in the Progression of Alzheimer’s Disease , 2014, PloS one.

[24]  J. Leszek,et al.  Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer's disease: a new approach to therapy. , 2013, CNS & neurological disorders drug targets.

[25]  M. Behari,et al.  Role of platelets in neurodegenerative diseases: a universal pathophysiology , 2013, The International journal of neuroscience.

[26]  D. Ben-shachar,et al.  Platelets: A possible glance into brain biological processes in schizophrenia. , 2012, World journal of psychiatry.

[27]  K. Preissner,et al.  The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice. , 2012, American journal of physiology. Cell physiology.

[28]  M. Gallagher-Jones,et al.  A benchmarked protein microarray-based platform for the identification of novel low-affinity extracellular protein interactions , 2012, Analytical biochemistry.

[29]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[30]  S. Strickland,et al.  Alzheimer's disease peptide β-amyloid interacts with fibrinogen and induces its oligomerization , 2010, Proceedings of the National Academy of Sciences.

[31]  Christoph Laske,et al.  Predictive Value of Platelet Activation for the Rate of Cognitive Decline in Alzheimer's Disease Patients , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  S. Strickland,et al.  Fibrinogen and β-Amyloid Association Alters Thrombosis and Fibrinolysis: A Possible Contributing Factor to Alzheimer's Disease , 2010, Neuron.

[33]  C. Gleissner,et al.  Identification of novel downstream targets of platelet glycoprotein VI activation by differential proteome analysis: implications for thrombus formation. , 2010, Blood.

[34]  S. Strickland,et al.  Fibrinogen, a possible key player in Alzheimer’s disease , 2009, Journal of thrombosis and haemostasis : JTH.

[35]  R. Flaumenhaft,et al.  Platelet alpha-granules: basic biology and clinical correlates. , 2009, Blood reviews.

[36]  M. Elvers,et al.  Rac1 is essential for phospholipase C-γ2 activation in platelets , 2009, Pflügers Archiv - European Journal of Physiology.

[37]  C. Laske,et al.  Association of platelet-derived soluble glycoprotein VI in plasma with Alzheimer's disease. , 2008, Journal of psychiatric research.

[38]  B. Nieswandt,et al.  Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. , 2005, Blood.

[39]  A. M. Clarfield,et al.  The decreasing prevalence of reversible dementias: an updated meta-analysis. , 2003, Archives of internal medicine.

[40]  B. Nieswandt,et al.  Long-Term Antithrombotic Protection by in Vivo Depletion of Platelet Glycoprotein VI in Mice , 2001, The Journal of experimental medicine.

[41]  S. Watson,et al.  LAT Is Required for Tyrosine Phosphorylation of Phospholipase Cγ2 and Platelet Activation by the Collagen Receptor GPVI , 1999, Molecular and Cellular Biology.

[42]  Martine,et al.  Immobilized fibrinogen activates human platelets through glycoprotein , 2018 .

[43]  X. Tong,et al.  Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[44]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[45]  H. Braak,et al.  Pattern of brain destruction in Parkinson's and Alzheimer's diseases , 2005, Journal of Neural Transmission.